Gujarat Themis Biosyn Ltd. moves to reshape its capital structure

The QIP mandate is for up to Rs 1,000 Crores; it does not fix a single share count. At the announced floor price of Rs 372.57 per share, the maximum raise would imply approximately 2.684 Crore new equity shares. If the permitted 5% discount is fully used, the number rises to approximately 2.825 Crore shares. The calculations assume the full Rs 1,000 Crores is raised and no interim change in the existing share count. ^{[1] [2]}

Promoter dilution: if the promoter group does not participate, its absolute shareholding would remain unchanged but its ownership percentage would fall from approximately 49.31% to 39.57% at the floor price, or to approximately 39.16% if the full 5% discount is used. PBGIL’s holding would reduce from 46.54% to roughly 37.33% or 36.95%, while Sachin Patel’s 2.77% would reduce to roughly 2.23% or 2.20%, respectively. These are derived figures based on the disclosed holdings and the two QIP share-count scenarios. ^{[5] [3] [4] [2]}

Implication: the authorization represents potential issuance equivalent to roughly one-quarter of the current outstanding shares, making it material relative to the existing capital base. It would not, on these assumptions, remove promoter control, but it would reduce the promoter block from about half the company to roughly 39%-40% post-issue. The actual dilution will be lower if the company raises less than Rs 1,000 Crores or prices the QIP above the floor.

Verdict: The latest QIP disclosure does not identify a specific project, capex budget, or quantified working-capital requirement as the purpose of the raise. The stated use is broad—growth strategy, strategic projects and general corporate purposes ^[6]. However, the financial profile suggests that capacity-related capex is the more evident funding need, with working capital an additional liquidity requirement rather than the explicitly disclosed primary driver.

Capex and working-capital signals

• Capex intensity: TTM capex was Rs 172.53 Crores through Q4 FY26, broadly matching TTM investing cash outflow of Rs 172.28 Crores ^{[7] [8]}. Capital work in progress stood at Rs 121.13 Crores in the latest reported balance-sheet snapshot ^[9]. This indicates that the company has had a substantial ongoing investment program, although the QIP filing does not specify the assets, capacity additions or commissioning timetable to be funded.
• Working capital: The latest standalone snapshot shows a current ratio of 1.12x, inventory days of 201.10 days and receivable days of 96.80 days ^{[10] [11] [12]}. These metrics point to capital being tied up in operations, but no separate rupee amount for incremental working capital has been disclosed in the QIP announcement.
• Disclosure scope: The latest board filing confirms approval of the preliminary placement document and opening of the QIP, but the cited filing primarily covers the issue authorization and pricing framework rather than a project-wise deployment schedule ^[13].

Alignment with leverage and cash flow

• Standalone debt-to-equity was 0.56x in Q1 FY27, versus 0.26x in Q2-Q3 FY26; net debt-to-equity was 0.54x ^{[14] [15]}. Total debt was Rs 159.86 Crores, against net debt of Rs 156.74 Crores and cash of only Rs 3.12 Crores ^{[16] [17] [18]}.
• TTM operating cash flow was Rs 48.78 Crores, compared with Rs 172.53 Crores of capex; derived capex coverage from operating cash flow was therefore approximately 28.27% ^{[19] [7]}.
• TTM financing cash flow was positive at Rs 114.93 Crores, while TTM net cash flow remained negative at Rs 8.57 Crores ^{[20] [21]}.

Implication: The equity fundraise is financially consistent with funding further investment without adding proportionately to already higher leverage. It also addresses the limited cash buffer and the gap between internally generated operating cash and recent capex. The key uncertainty is that the company has not yet disclosed how much of the proceeds will go to capex versus working capital, nor which specific projects will receive the funds.

Verdict: Gujarat Themis Biosyn is among the most leveraged companies in the comparison set on a net basis. In Q1 FY27, standalone gross debt/equity was 0.56x and net debt/equity 0.54x, with Rs 159.86 Crores of debt against only Rs 3.12 Crores of cash ^{[14] [15] [22] [18]}. Only Gufic had a higher gross debt/equity ratio at 0.58x, while Gujarat Themis had the highest net debt/equity ratio among the companies compared.

The QIP therefore looks less like a pure “aggressive capacity expansion” transaction and more like a balance-sheet repair and financing-flexibility exercise with growth optionality. The stated use of proceeds includes debt repayment as well as capex, working capital, subsidiaries and acquisitions; the eventual signal will depend on the actual allocation.

Gujarat Themis Biosyn

Leverage increased materially over the recent period: standalone debt/equity moved from 0.26x in Q2-Q3 FY26 to 0.56x in Q4 FY26 and Q1 FY27 ^[14]. Net debt rose from Rs 62.60 Crores to Rs 156.74 Crores over the same comparison ^[17]. The balance sheet is not currently showing debt-service stress—Q1 FY27 interest coverage was 11.69x ^[23]—but liquidity is relatively tight, with a 1.12x current ratio ^[10]. ROCE was only 4.8% in Q1 FY27, which means the incremental capital has not yet translated into a high reported return profile ^[24].

Aarti Drugs

Aarti Drugs had lower relative leverage but materially higher absolute borrowings. Q1 FY27 consolidated debt/equity was 0.37x and net debt/equity 0.37x, with total debt of Rs 574.83 Crores and net debt of Rs 567.56 Crores ^{[25] [26] [27] [28]}. Interest coverage was 10.74x ^[29]. Thus, Aarti is more debt-funded in absolute terms, but its equity base absorbs that debt better than Gujarat Themis’s current balance sheet.

Gufic Biosciences

Gufic is the closest high-leverage comparator on a gross basis. Its Q1 FY27 consolidated debt/equity was 0.58x and net debt/equity 0.49x, with debt of Rs 385.17 Crores and net debt of Rs 322.98 Crores ^{[30] [31] [32] [33]}. Its 5.05x interest coverage was weaker than Gujarat Themis’s ^[34]. The comparison suggests that Gujarat Themis’s key relative weakness is not gross leverage alone, but the combination of high net leverage and a very small cash buffer.

Morepen Laboratories

Morepen is substantially less leveraged relative to equity: Q1 FY27 consolidated debt/equity was 0.16x and net debt/equity 0.13x ^{[35] [36]}. Debt was Rs 194.69 Crores, net debt Rs 163.50 Crores, and cash Rs 31.19 Crores ^{[37] [38] [39]}. Interest coverage of 18.12x was also stronger than Gujarat Themis’s ^[40]. Morepen has a similar net-debt amount in absolute terms, but considerably lower balance-sheet dependence on external financing.

Unichem Laboratories

Unichem’s latest available consolidated snapshot is Q4 FY26, one quarter older than the Q1 FY27 figures above. Debt/equity was 0.17x and net debt/equity only 0.07x ^{[41] [42]}. Although total debt was Rs 468.78 Crores, cash of Rs 289.48 Crores reduced net debt to Rs 179.30 Crores ^{[43] [44] [45]}. Its 2.48x current ratio also provides a larger liquidity cushion than Gujarat Themis’s 1.12x ^{[46] [10]}. Unichem is therefore a case where absolute debt is high but net reliance on financing is comparatively low.

Novartis India

Novartis India is a debt-free balance-sheet benchmark rather than a directly comparable leverage peer. On its Q4 FY26 standalone figures, total debt was zero, net debt/equity was -0.06x, cash was Rs 52.50 Crores, and interest coverage was 437.57x ^{[47] [48] [49] [50]}. Its 5.30x current ratio is also well above Gujarat Themis’s ^{[51] [10]}. The API operating comparability of this roster is imperfect; the financial comparison is therefore directional.

What the QIP is signalling

The reported proposal seeks approval for up to Rs 1,000 Crores through a QIP and authorization to issue up to Rs 1,500 Crores of debt securities ^[52]. Reported uses include:

• prepayment of existing borrowings;
• capital expenditure and working capital;
• investments in subsidiaries;
• inorganic growth and acquisitions ^[53].

The QIP ceiling is approximately 6.26x Gujarat Themis’s current gross debt, derived from the proposed Rs 1,000 Crores ^[52] and Q1 FY27 gross debt of Rs 159.86 Crores ^[22]. If raised and used substantially for repayment, it could transform the leverage profile. However, that is not yet the stated allocation outcome.

The simultaneous debt-issuance mandate is important: it preserves the ability to fund expansion with borrowings, so the transaction is not an unambiguous deleveraging commitment. Conversely, because debt repayment is explicitly included and no project-level capacity addition, commissioning timetable or acquisition target is identified, the QIP does not yet establish an aggressive expansion programme.

Analyst read: the immediate strategic shift is toward capital-structure flexibility after a recent leverage step-up. Deleveraging is the more credible near-term interpretation if the QIP is used for borrowing prepayment. An aggressive capacity-expansion interpretation would require subsequent evidence of a completed issue, disclosed capex projects, capacity targets, acquisition deployment and corresponding improvement in asset returns.